UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):March 27, 2003
TELIK, INC.
(Exact name of registrant as specified in its charter)
Delaware
| | 000-31265
| | 93-0987903
|
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
3165 Porter Drive, Palo Alto, CA (Address of principal executive offices) | | 94304 (Zip Code) |
Registrant’s telephone number, including area code: (650) 845-7700
750 Gateway Boulevard
South San Francisco, CA 94080
(Former name or former address, if changed since last report)
Item 5. Other Events and Regulation FD Disclosure.
On March 27, 2003, Telik, Inc. announced the initiation of a randomized, controlled Phase 3 registration trial of TLK286 administered as a single agent in ovarian cancer patients whose disease has progressed following platinum-based chemotherapy and one second-line treatment. A copy of the press release with respect to this matter is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 7. Financial Statements, Pro Form Financial Information and Exhibits
(c) Exhibits
Number
| | Description
|
|
99.1 | | Press Release entitled “Telik Initiates Phase 3 Registration Trial of TLK286 in Ovarian Cancer Patients,” dated March 27, 2003. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | TELIK, INC |
|
Date: March 27, 2003 | | /s/ CYNTHIA M. BUTITTA
Cynthia M. Butitta, Chief Operating Officer and Chief Financial Officer |
EXHIBIT INDEX
Number
| | Description
|
|
99.1 | | Press Release entitled “Telik Initiates Phase 3 Registration Trial of TLK286 in Ovarian Cancer Patients,” dated March 27, 2003. |
